Loading
Korsana Biosciences, Inc. Stock: price and insider trades · United States
US·Mcap US$1.6B
No insider purchase over the last 90 days. The latest was filed 07 Jun 2021.
Korsana Biosciences, Inc.: what insiders have been doing
This page follows insider dealings at Korsana Biosciences, Inc. as filed with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 7 filings signed by 4 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
There has been no open-market purchase by an insider of Korsana Biosciences, Inc. for at least a year. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 7 filings, this issuer sits below that mark. Our records for Korsana Biosciences, Inc. go back to 2021, with 5 purchases and 2 sales on the open market in total.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€6M
5 ops. · all time
Sell Volume
€526,383
2 ops. · all time
Who traded when
BuySaleSlate Path Capital LP1 sale
Since the insiders bought
- -80.5%Entry US$574.00 · Close at T+365 US$111.86
- -80.5%Entry US$574.00 · Close at T+365 US$111.86
- -80.5%Entry US$574.00 · Close at T+365 US$111.86
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Korsana Biosciences, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$44.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$34.32
Analyst consensus
5 analystsStrong buy
US$8.00Target US$44.00(+28%)US$70.00
Income statement
RevenueUS$2M
EBITDA-US$37.3M-1849% margin
Net income-US$35.6M0.0% margin
Valuation
PER (forward)-9.7x
Beta1.73
Balance sheet & cash
Market capUS$1.6B
Free Cash Flow-US$22.4M
Debt / Equity1%
Profitability & ownership
% insiders0.3%
% institutions30.1%
Last declaration on 23 September 2026
Declarations23 total
4,903 shares@ US$34.9968.7% of flowCommonSEC144:0001950047-26-009776
100 shares@ US$34.991.4% of flowCommonSEC144:0001950047-26-009757
2,139 shares@ US$34.9929.9% of flowCommonSEC144:0001950047-26-009679
25,000 shares@ US$2.3550.37% mcap100.0% of flowCommon Stock, no par valueSEC:0001193125-26-355721:0
55,849 shares@ US$3.301.16% mcap50.0% of flowCommon Stock, no par valueSEC:0001193125-26-355707:0
48,629 shares@ US$3.791.16% mcap50.0% of flowCommon Stock, no par valueSEC:0001193125-26-355707:1
351,037 sharesCommon StockSEC:0001193125-26-309048:0
181,818 shares@ US$2.758.1% of flowCommon StockSEC:0000950170-25-046280:0
9,090 shares@ US$2.75100.0% of flowCommon StockSEC:0000950170-25-046099:0
357,880 shares@ US$1.551117.6% of flowCommon Stock, no par valueSEC:0000902664-24-006775:0
15,000 shares0Common StockSEC:0000950170-24-007920:0
50,000 shares0Common StockSEC:0000950170-24-007917:0
20,000 shares0Common StockSEC:0000950170-23-067734:0
20,000 shares0Common StockSEC:0000950170-23-067736:0
5,000 shares0Common StockSEC:0000950170-23-067740:0
20,000 shares0Common StockSEC:0000950170-23-067738:0
8 shares@ US$3.3950.0% of flowCommon StockSEC:0000899243-23-018047:0
225,000 shares@ US$8.6831.9% of flowCommon StockSEC:0001140361-23-026101:0
823,170 shares@ US$3.2839.2% of flowCommon StockSEC:0001140361-21-020090:0
Canonical exit: 1 Sept 2021 (T+90)
92,831 shares@ US$3.12100.0% of flowCommon StockSEC:0000899243-21-022327:0
Canonical exit: 1 Sept 2021 (T+90)
961,538 shares@ US$3.1282.4% of flowCommon Stock, no par valueSEC:0000902664-21-003032:0
Canonical exit: 1 Sept 2021 (T+90)
302,000 shares@ US$2.4310.7% of flowCommon StockSEC:0001140361-21-016532:0
Canonical exit: 4 Aug 2021 (T+90)
300,000 shares@ US$2.2910.1% of flowCommon StockSEC:0001140361-21-016304:0
Canonical exit: 2 Aug 2021 (T+90)
23 of 23 declarations
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. is a company focused on developing biopharmaceutical solutions. It emphasizes innovation in the life sciences sector.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
